Impact of Age on the Cancer-Specific Survival of Patients with Localized Renal Cell Carcinoma: Martingale Residual and Competing Risks Analysis

Muyan Cai1,2,*, Jinhuan Wei1,3, Zhiling Zhang3, Hongwei Zhao4, Yunqiao Qiu5, Yong Fang1, Zhenli Gao4, Jiazheng Cao1, Wei Chen1, Fangjian Zhou3, Dan Xie2, Junhang Luo1

1 Department of Urology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China, 2 Department of Urology, Cancer Center, Sun Yat-Sen University, Guangzhou, China, 3 Department of Urology, Guangzhou Hospital of Guangdong Academy of Medical Sciences, Guangzhou, China, 4 Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao University Medical College, Yantai, China, 5 Department of Urology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China

Abstract

Background: Age at diagnosis has been shown to be an independent prognostic factor of localized renal cell carcinoma (RCC) in several studies. We used contemporary statistical methods to reevaluate the effect of age on the cancer-specific survival (CSS) of localized RCC.

Methods and Findings: 1,147 patients with localized RCC who underwent radical nephrectomy between 1993 and 2009 were identified in our four institutions. The association between age and CSS was estimated, and the potential threshold was identified by a univariate Cox model and by martingale residual analysis. Competing risks regression was used to identify the independent impact of age on CSS. The median age was 52 years (range, 19–84 years). The median follow-up was 61 months (range, 6–144 months) for survivors. A steep increasing smoothed martingale residual plot indicated an adverse prognostic effect of age on CSS. The age cut-off of 45 years was most predictive of CSS on univariate Cox analysis and martingale residual analysis (p = 0.005). Age ≤45 years was independently associated with a higher CSS rate in the multivariate Cox regression model (HR = 1.59, 95% CI = 1.05–2.40, p = 0.027) as well as in competing risks regression (HR = 3.60, 95% CI = 1.93–6.71, p = 0.001).

Conclusions: Increasing age was associated with a higher incidence of cancer-specific mortality of localized RCC. Age dichotomized at 45 years would maximize the predictive value of age on CSS, and independently predict the CSS of patients with localized RCC.

Citation: Cai M, Wei J, Zhang Z, Zhao H, Qiu Y, et al. (2012) Impact of Age on the Cancer-Specific Survival of Patients with Localized Renal Cell Carcinoma: Martingale Residual and Competing Risks Analysis. PLoS ONE 7(10): e48489. doi:10.1371/journal.pone.0048489

Editor: Lawrence Kazembe, Chancellor College, University of Malawi, Malawi

Received June 26, 2012; Accepted September 26, 2012; Published October 30, 2012

Copyright: © 2012 Cai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The work was supported by the National Natural Science Foundation of China (30900539,81172429), and the Fundamental Research Funds for the Central Universities (09ykpy35). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: bxied@mail.sysu.edu.cn (DX); luojunh@mail.sysu.edu.cn (JHL)

† These authors contributed equally to this work.

Introduction

Age at diagnosis has been demonstrated to be is a prognostic factor for the cancer-specific survival (CSS) of some kinds of human cancers, including renal cell carcinoma (RCC) [1–15]. These findings help oncologist to select more appropriate therapy strategy for different age group of cancer patients[16–20]. The previous studies always only considered cancer-specific mortality and neglected other cause mortality when age at diagnosis was demonstrated to be an independent prognostic factor for CSS, but other cause mortality rates may vary according to age, and other cause mortality reduces the pool of individuals at risk of cancer-specific mortality, these may lead to the overestimate of the impact of age on CSS. Recently, competing risks regression model was recommended to eliminate this limitation [21,22].

Secondly, the selection of age cut-off point was arbitrary when the effect of age on the prognosis of cancer patients had been estimated in the previous studies. If statistical analysis was used to select the optimal age cutout point which could best separate patients at a high and a low risk of cancer-specific mortality, the results would be more valuable for therapy selection and patient counseling. Herein, martingale residual analysis was used to select the optimal age cutout point that would maximize the predictive value of age on the CSS of localized RCC, and competing risks regression was used to identify the independent impact of age on CSS by adjusting other cause mortality.
Materials and Methods

Patients

By using the departmental surgical database of our four institutions (First Affiliated Hospital and Cancer Center of Sun Yat-Sen University, Yantai Yuhuangding Hospital, and First Affiliated Hospital of GuangZhou University of Chinese Medicine), we identified 1,147 patients who had treated with radical nephrectomy for unilateral, sporadic localized RCC (T1–T2, N0, and M0) between 1993 and 2009. The ethics committees at Sun Yat-Sen University, Yantai Yuhuangding Hospital, and GuangZhou University of Chinese Medicine approved of the study and waived the need for consent. Data collected from each patient included age at diagnosis, gender, BMI (body mass index), ECOG PS (Eastern Cooperative Oncology Group performance status), tumor side, TNM stage, Fuhrman grade, histological subtype, and survival time. Tumors were classified in accordance with the 2002 TNM staging system. The grading system used in the study was based on the Fuhrman four-grade. Histological subtypes were stratified in accordance with the 2002 AJCC/UICC classification, and only tumors of clear-cell, chromophobe, and papillary histology were included. We classified cause of death as either RCC-related or as other-cause-related. Overall survival time was determined from the date of surgery to the date of death from any cause or last follow-up. CSS time was determined from the date of surgery to the date of death from RCC or last follow-up.

Statistical Analysis

To identify a potential threshold between the younger and the older patients, a range of possible age cut-off values were estimated and tested in a univariate Cox proportional hazard regression model. In order to gain more insight into the dependence of CSS on age, a multiple Cox proportional hazard model was used [23]. Firstly, a Cox regression model excluding age as a factor was fitted. Then, functional shape was checked in the Cox regression model for the covariate by means of a smoothed martingale residual plot. A cut-off value should be considered if a steep increase or decrease of the resulting smoothing line crossed the null line of the x axis at the respective age.

The survival rates were calculated by the Kaplan–Meier method, and differences were determined by log-rank test. The prognostic significance of certain factors was assessed by the Cox regression model. The effect of other-cause mortality cannot be accounted for in Cox regression model. This may in turn result in the overestimate of the effect of cancer-specific mortality. The use of competing risks regression (Fine and Gray’s regression) can remove this limitation [24]. Competing risks regression was used to test the significance of cancer-specific mortality predictors after accounting for other-cause mortality.

Probability values of \( p < 0.05 \) were considered significant. R version 2.11.1 (R Foundation for Statistical Computing, Vienna, Austria) was used for all calculations pertaining to Fine and Gray’s regression. The SAS version 9.1.3 (SAS Institute, Cary, NC, USA) was used for all other calculations.

Results

Clinical Outcome

Patient demographic data are presented in Table 1. The mean age was 51.3 years (range, 19–84 years; median, 52 years). The median follow-up was 61 months (range, 6–144 months) for survivors. Of the patients, 124 of them died of RCC during follow-up, and 78 died of other causes. The 3-, 5-, and 7-year CSS rates were 95.1%, 90.4% and 85.2%, the 3-, 5-, and 7-year non-kidney-
The Optimal Age Cutpoint Selected by Univariate Cox Regression

To identify the optimal age cut-off point that would maximize the predictive value of age on CSS, the patients were then divided into two groups at each age cut-off, from 35 years to 70 years, at five-year intervals. Univariate Cox regression demonstrated that the age cut-off of 45 years led to the highest significant difference in CSS between the respective defined subgroups (HR = 1.78, 95% CI = 1.18–2.67, p = 0.005; Table 2).

The Optimal Age Cutpoint Selected by Martingale Residual

The multivariate Cox proportional hazard model was used to further confirm the optimal age cut-off point. A steep increasing smoothed martingale residual plot indicated an adverse prognostic effect of age on CSS. The martingale residual curve crossed the null line at 46 years of age with martingale residual (Figure 2). Therefore, in multiple analysis, 45 years of age was also demonstrated to be the optimal age cut-off point that would maximize the predictive value of age on the CSS.

### Table 1. Demographic and clinical data.

| Characteristics                        | Results                  |
|----------------------------------------|--------------------------|
| Age, median (range), yr                | 52 (19–84)               |
| Gender, No. (%)                        |                          |
| Male                                   | 754 (65.7%)              |
| Female                                 | 393 (34.3%)              |
| Tumor side, No. (%)                    |                          |
| Left                                   | 591 (51.5%)              |
| Right                                  | 556 (48.5%)              |
| Histological subtype, No. (%)          |                          |
| Clear                                  | 927 (80.8%)              |
| Papillary                              | 161 (14.0%)              |
| Chromophobe                            | 59 (5.2%)                |
| Fuhrman grade, No. (%)                 |                          |
| G1                                     | 383 (33.4%)              |
| G2                                     | 508 (44.3%)              |
| G3/4                                   | 256 (22.3%)              |
| Tumor stage, No. (%)                   |                          |
| pT1a                                   | 369 (32.2%)              |
| pT1b                                   | 465 (40.5%)              |
| pT2                                   | 313 (27.3%)              |
| BMI, No. (%)                           |                          |
| <25 kg/m²                              | 720 (62.8%)              |
| ≥25 kg/m²                              | 427 (37.2%)              |
| ECOG PS, No. (%)                       |                          |
| 0                                      | 903 (78.7%)              |
| ≥1                                     | 244 (21.3%)              |

### Table 2. Univariate Cox proportional hazard regression model of different age cutoffs in patients with local RCC treated with radical nephrectomy.

| Cutoff Point (years) | Categories | HR   | 95% CI | p value |
|----------------------|------------|------|--------|---------|
| 35                   | ≤35(n = 121) vs >35(n = 1026) | 2.07 | 0.96–4.43 | 0.062 |
| 40                   | ≤40(n = 258) vs >40(n = 887) | 1.87 | 1.14–3.09 | 0.013 |
| 45                   | ≤45(n = 408) vs >45(n = 739) | 1.78 | 1.18–2.67 | 0.005 |
| 50                   | ≤50(n = 565) vs >50(n = 582) | 1.60 | 1.11–2.29 | 0.011 |
| 55                   | ≤55(n = 711) vs >55(n = 436) | 1.49 | 1.05–2.13 | 0.025 |
| 60                   | ≤60(n = 851) vs >60(n = 290) | 1.39 | 0.95–2.02 | 0.083 |
| 65                   | ≤65(n = 961) vs >65(n = 186) | 1.40 | 0.91–2.16 | 0.123 |
| 70                   | ≤70 (n = 1057) vs >70(n = 90) | 1.46 | 0.82–2.60 | 0.194 |

Survival Analysis in the Cox Regression Model

We defined age ≤45 years old and >45 years old as the younger group and the older group, respectively. The association between CSS and age (HR = 1.59, 95% CI = 1.05–2.40, p = 0.027), Fuhrman grade (HR = 1.38, 95% CI = 1.08–1.78, p = 0.011), stage (HR = 1.42, 95% CI = 1.10–1.82, p = 0.006), and ECOG PS (HR = 1.63, 95% CI = 1.11–2.41, p = 0.013) were statistically significant in univariate and multivariate Cox regression analysis (Table 3).

Survival Analysis Adjusted by Competing Risks Regression

Of all patient deaths, 38.6% (78/202) were directly attributable to non-kidney cancer causes. Figure 3 presents the distribution of health status of the younger group and the older group, and the younger group patients had a significantly lower cancer-specific mortality. Figure 4 presents the contribution of all risk factors to cancer-specific mortality, after accounting for other-cause mortality. On multivariate competing risks regression, we complemented our analyses with competing risks regression, which addressed the significance of the combined multivariate contribution of all risk factors to cancer-specific mortality, after accounting for other-cause mortality. On multivariate competing risks regression analysis, an age of under 45 years was found to be an independent prognostic factor for better CSS of localized RCC (HR = 3.60, 95% CI = 1.93–6.71, p = 0.001). Of the other variables that were significant in univariate analysis, stage (HR = 0.73, 95% CI = 0.55–0.97, p = 0.030) and ECOG PS (HR = 2.73, 95% CI = 1.75–4.27, p = 0.001) were shown to be independent prognostic factors. However, pathologic subtype, and Fuhrman grade were no longer regarded as being the predictors of CSS (Table 4).

Discussion

Several previous studies have indicated that increased age was correlated with poor CSS for RCC [9,10]. Traditionally, the prognosis factors which are used to predict the CSS of patients with RCC also include stage, nuclear grade, histological subtype, tumor size, and performance status [25–27]. When a continuous
Figure 2. Martingale residual analysis. (A) Scatterplot of age vs martingale residual of Cox proportional hazard model. The smoothed curves crossed the null line at 46 years. (B) Age distribution of 1,147 patients with localized RCC. doi:10.1371/journal.pone.0048489.g002

Table 3. Univariable and multivariate analysis with Cox regression model for risk factors predictive of CSS.

| Characteristics                     | Univariate Analysis | Multivariate Analysis |
|-------------------------------------|---------------------|-----------------------|
|                                     | HR(95% CI)          | p value               |
| Gender (Male vs Female)             | 0.81 (0.55–1.19)    | 0.284                 |
| Tumor stage (pT1a vs pT1b vs pT2)   | 1.76(1.39–2.23)     | <0.001                |
| Age (<45 vs >45 years old)          | 1.78(1.18–2.67)     | 0.005                 |
| Histological subtype (Clear vs Papillary vs Chromophobe) | 0.58(0.38–0.87) | 0.008 |
| Fuhrman grade (G1 vs G2 vs G3/4)    | 1.64(1.28–2.08)     | <0.001                |
| Tumor side (Left vs Right)          | 1.18(0.83–1.67)     | 0.366                 |
| BMI (<25 vs ≥25)                    | 0.67(0.46–0.98)     | 0.041                 |
| ECOG PS (0 vs ≥1)                   | 2.26(1.56–3.26)     | <0.001                |

doi:10.1371/journal.pone.0048489.t003
variable was demonstrated to be a prognosis factor, the selection of the optimal cut-off point could maximize its predictive value and to best separate the patients with high risk of cancer death from patients with low risk due to tumor progression. Similar to the way in which tumor size is a predictor of CSS in localized RCC, increased tumor size was associated with poor CSS for localized RCC. Previous studies demonstrated that the 7 cm cut-off point led to the highest significant difference prognosis of localized RCC. Therefore, the T1 tumors were defined as being the organ-confined tumors of 7 cm or less in size, and the T2 tumors as being those larger than 7 cm in the current TNM classification of RCC [28,29].

Taccon et al [12] demonstrated that young patients, defined as those who were ≤40 years old, had better 5-year CSS rates than older patients (90.8% vs 78.3%; \( p = 0.005 \)). An age under 40 years old was an independent prognostic factor for the CSS of patients with RCC (\( p = 0.047 \)). Taccon selected 40 years of age as the age cut-off point. This was based on previous studies concerning early-onset breast and colon cancers at or before 40 years of age, which suggested that there were differences in the natural history of these cancers for young patients. Jung et al [13] divided 619 patients with RCC into two groups according to age at diagnosis, ≤55 or >55 years of age. The younger group had a greater 5-year CSS rate than the older group (88.9% vs 76.3%, \( p<0.001 \)), and Jung selected this threshold as a prognostic cut-off point because the median patient age was 55 years old. In two other similar studies, a young patient was defined as one being under 50 years old, CSS rates were also significantly higher for younger patients compared to the older patients with RCC [14,15].

Martingale residual analysis is always used to identify the optimal cut-off point of a continuous variable to best separate patients at a high and a low risk of disease progression. Soares et al [30] estimated the effect of age on six-month survival of 862 patients who were critically ill with cancer, and martingale residual analysis was used to divide the population into young (<60 years) and older patients (>60 years), resulting in higher survival rates for younger patients.
predictor of prostate-cancer-specific survival after controlling for other-cause mortality. Age had a strong negative impact on mortality rates among men with increasing age (unadjusted Kaplan–Meier survival curves showed decreasing survival, and a cut-off point of 10 cm separated two populations with the largest event-free survival difference [31]. Herein, martingale residual analysis was used to determine the optimal age cut-off point. A steep increasing smoothed martingale residual plot indicated an adverse prognostic effect of age on CSS. We found no cut-off point other than that of 45 years to be more suitable for distinguishing between the younger and the older patients with localized RCC that would maximize the predictive value of age on the CSS.

In the current study, over one-third of all patient deaths were directly attributable to non-kidney cancer causes. The adjustment for other-cause mortality is important because other-cause mortality reduces the pool of individuals at risk of cancer-specific mortality, and it leads to the overestimate of the importance of cancer-related deaths. The effect of other-cause mortality was neglected in Cox regression models; the use of competing risks regression models can eliminate this limitation [21,22]. Several studies have shown that older men are more likely to be diagnosed as having high-risk prostate cancer and as having lower CSS [32,33]. Recently, Bechis et al [22] investigated 11,790 men in the Cancer of CaPSURE database with complete risk, treatment, and follow-up information. Competing risks regression was used to identify whether a patient’s age at diagnosis is the independent predictor of his CSS. The study showed that age was a univariate predictor of both overall and prostate-cancer-specific mortality; unadjusted Kaplan–Meier survival curves showed decreasing survival rates among men with increasing age ($p<0.01$). However, on multivariate competing risks analysis, age was no longer a predictor of prostate-cancer-specific survival after controlling for treatment modality and disease risk. Therefore, an independent predictor of CSS in univariate and multivariate Cox regression models does not always have predictive value after accounting for other risks of death on competing risks analysis. Herein, multivariate competing risks regression analysis was used to further confirm the impact of age on CSS, and an age under 45 years old was found to be an independent prognostic factor for better CSS of localized RCC. Of the other variables that were significant in univariate analysis, stage and ECOG PS were shown to be independent prognostic factors. However, pathologic subtype and Fuhrman grade were no longer the predictors of CSS.

Herein, the study population comes from China, it is uncertain whether the conclusions in this study are accurate for the populations of other countries. However, the optimal cut-off point analysis and the competing risks regression analysis utilized in this study also have applicability to assess the impact of age on the prognosis of human cancers in other studies.

In summary, our study reconfirmed that the increasing age of patients with localized RCC was associated with a higher incidence of cancer-specific mortality. We demonstrated that 45 years old was the optimal age cut-off point that would maximize the predictive value of age on a patient’s CSS, and age dichotomized at 45 years old was an independent predictor of cancer-specific mortality in the multiple Cox regression model as well as in the competing risks regression. The optimal cut-off point analysis utilized in this study also has applicability to assess the impact of age on CSS of other cancers.

**Author Contributions**

Conceived and designed the experiments: JHL DX. Performed the experiments: JHW. Analyzed the data: ZLZ HWZ YF ZLG JZC. Contributed reagents/materials/analysis tools: YQQ ZLG FJZ WC JHL. Performed the experiments: JHW. Analyzed the data: ZLZ HWZ YF ZLG JZC. Contributed reagents/materials/analysis tools: YQQ ZLG FJZ WC JHL. DX. Wrote the paper: MYC JHW JHL DX.

---

**References**

1. Domergue J, Ismail M, Astre C, Saint-Aubert B, Joyeux H, et al. (1988) Colorectal carcinoma in patients younger than 40 years of age. Montpellier Cancer Institute experience with 78 patients. Cancer 61: 835–840.

2. Chung M, Chang HR, Bland KL, Wanebo HJ (1996) Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 77: 97–103.

3. Vinh-Hung V, Joseph SA, County N, Ly BH, Vlastos G, et al. (2010) Age and axillary lymph node ratio in postmenopausal women with T1–T2 node positive breast cancer. Oncologist 15: 1050–1062.

4. Haymart MR (2009) Understanding the Relationship Between Age and Thyroid Cancer. Oncologist 14: 216–221.

5. Voutilainen PE, Miettinen MM, Leppänen AK, Haglund CH, Haapianen RK, et al. (2001) Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid 11: 953–957.

---

**Table 4.** Univariable and multivariable competing risks regression models for prediction of cancer-specific survival after accounting for other-cause mortality.

| Characteristics | Univariate Competing Risks Regression | Multivariate Competing Risks Regression |
|-----------------|---------------------------------------|----------------------------------------|
|                 | HR(95% CI) p value                      | HR(95% CI) p value                      |
| Gender (Male vs Female) | 0.80(0.54–1.18) 0.280 | 1.22(0.76–1.98) 0.404 |
| Tumor stage (pT1a vs pT1b vs pT2) | 1.45(1.12–1.88) **0.004** | 0.73(0.55–0.97) **0.030** |
| Age(45 years vs >45 years old) | 1.52(1.01–2.29) **0.044** | 3.60(1.93–6.71) **0.001** |
| Histological subtype (Clear vs Papillary vs Chromophobe) | 0.60(0.39–0.91) **0.018** | 1.03(0.70–1.51) **0.883** |
| Fuhrman grade (G1 vs G2 vs G3/4) | 1.36(1.06–1.76) **0.015** | 1.03(0.75–1.42) **0.832** |
| Tumor side (Left vs Right) | 1.23(0.86–1.77) 0.250 | 0.89(0.56–1.40) 0.617 |
| BMI (<25 vs ≥25) | 0.69(0.46–1.03) 0.073 | 1.06(0.67–1.67) 0.791 |
| ECOG PS (0 vs ≥1) | 1.63(1.10–2.42) **0.014** | 2.73(1.75–4.27) **0.001** |

---

**doi:10.1371/journal.pone.0048489.t004**
6. Pectasides D, Fountzilas G, Aravantinos G, Ramias A, Kalofonos HP, et al. (2007) Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Int J Gynecol Cancer 17: 1003–1010.

7. Nguyen NP, Ly BH, Bezo M, Vinh-Hung V. (2010) Importance of age as a prognostic factor for tonsillar carcinoma. Ann Surg Oncol 17: 2579–2577.

8. Brandt A, Bermejo JL, Sundquist J, Hemminki K (2009) Age at Diagnosis and Age at Death in Familial Prostate Cancer. Oncologist 14: 1209–1217.

9. Verhoest G, Veillard D, Guille F, De La Tuille A, Salomon L, et al. (2007) Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol 51: 1298–1304; discussion 1304–1295.

10. Jeong IG, Yoo GH, Song K, Park J, Cho YM, et al. (2009) Age at diagnosis is an independent predictor of small renal cell carcinoma recurrence-free survival. J Urol 182: 445–450.

11. Denzinger S, Otto W, Burger M, Hammerschmied C, Junker K, et al. (2007) Sporadic renal cell carcinoma in young and elderly patients: are there different clinicopathological features and disease specific survival rates? World J Surg Oncol 5: 16.

12. Taccoen X, Valeri A, Descotes JL, Morin V, Stindel E, et al. (2007) Renal cell carcinoma in adults 40 years old or less: young age is an independent prognostic factor for cancer-specific survival. Eur Urol 51: 980–987.

13. Jung EJ, Lee HJ, Kwak C, Kim JH, Moon KC (2009) Epithelial ovarian carcinoma in young patients: does young age have an independent prognostic significance? Gynecol Oncol 111: 139–143.

14. Karakiewicz PI, Jeldres C, Suardi N, Hutterer GC, Perrotte P, et al. (2008) Age as a prognostic factor for cancer-specific survival of low-stage clear cell renal cell carcinoma. Urology 73: 137–141.

15. Karakiewicz PI, Felders C, Saarela N, Hutterer GC, Perrotte P, et al. (2008) Age at diagnosis is a determinant factor of renal cell carcinoma survival in patients treated with nephrectomy. Can Urol Assoc J 2: 610–617.

16. Thoroddsen A, Einarsson GV, Hardarson S, Petursdottir V, Magnusson J, et al. (2008) Sporadic renal cell carcinoma in young compared to older patients: comparison of clinicopathologic risk factors and survival. Scand J Urol Nephrol 42: 121–125.

17. de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, et al. (1993) Age as prognostic factor in premenopausal breast cancer. Lancet 341: 1039–1043.

18. Guinee VF, Moller T (2000) Breast carcinoma in young patients. Lancet 356: 57–63.

19. Muss HB (2010) Climbing the mountain: breast cancer in seniors. Oncologist 15: 657–664.

20. Leonard RC, Barrett-Lee PJ, Gouein MA, Willett AM, Reed MW, et al. (2010) Effect of patient age on management decisions in breast cancer: consensus from a national consultation. Oncologist 15: 657–664.

21. Mell HK, Dignam JJ, Salama JK, Cohle EE, Polite BN, et al. (2010) Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol 28: 15–20.

22. Bechis SK, Carroll PR, Cooperberg MR. (2011) Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 29: 235–241.

23. Klein JP MM (1997) Survival analysis: techniques and application to coronary risk prediction. Epidemiology 20: 555–561.

24. Wolbers M, Koller MT, Wittenman JC, Steyerberg EW (2009) Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology 20: 555–561.

25. Sun M, Shariat SF, Cheng C, Ficarra V, Murat M, et al. (2011) Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 60: 644–661.

26. Karakiewicz PI, Briganti A, Chan FK, Trinh QD, Perrotte P, et al. (2007) Multinstitutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 25: 1316–1322.

27. Lam JS, Breda A, Belldegrun AS, Fidler RA (2006) Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol 24: 5565–5575.

28. Sobin LH, Fleming ID (1997) TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 90: 1803–1804.

29. Bedke J, Princh M, Buse S, Jakobi H, Elsaesser KH, et al. (2008) Prognostic stratification of localized renal cell carcinoma by tumor size. Urol J 180: 62–67.

30. Soares M, Carvalho MS, Salluh JI, Ferreira CG, Luiz RR, et al. (2006) Effect of age on survival of critically ill patients with cancer. Crit Care Med 34: 715–721.

31. Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, et al. (2008) Prognostic significance of age in head and neck cancer. J Clin Oncol 26: 445–448.

32. Klein JP MM (1997) Survival analysis: techniques and application to coronary risk prediction. Epidemiology 20: 555–561.

33. Konety BR, Cowan JE, Carroll PR (2008) Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol 179: 1797–1803.